HR 8630 Re-checks Congress.gov for new actions and updates the bill's status, and fills in any sponsors, committees, or related bills that are missing. It does not re-pull sponsors/cosponsors/committees/related — those rarely change — and it skips all work if nothing has changed upstream, so it's cheap to click.
To amend the Public Health Service Act to prohibit treatment of a biologic as a biological product based solely on the presence of a protein that is a clinically inactive component in such biologic, and for other purposes.
Summary
This bill amends the Public Health Service Act to modify how certain medications containing proteins are classified under federal law. Specifically, it prohibits treating a medication as a biological product based solely on the presence of a protein that is clinically inactive, meaning the protein does not have therapeutic effects. The bill includes a technical correction to the same section of law. The measure aims to prevent unnecessary regulatory classification of medications that contain non-functional proteins.
AI-generated plain-language summary of the bill text — neutral, and may be imperfect. See the full text below for the exact wording.
Sponsor (1)
11 cosponsors
- Rep. Babin, Brian [R-TX-36] (R-TX)
- Rep. Carter, Earl L. "Buddy" [R-GA-1] (R-GA)
- Rep. Carter, John R. [R-TX-31] (R-TX)
- Rep. Hamadeh, Abraham J. [R-AZ-8] (R-AZ)
- Rep. Harshbarger, Diana [R-TN-1] (R-TN)
- Rep. Kennedy, Mike [R-UT-3] (R-UT)
- Rep. Khanna, Ro [D-CA-17] (D-CA)
- Rep. Luttrell, Morgan [R-TX-8] (R-TX)
- Rep. McCaul, Michael T. [R-TX-10] (R-TX)
- Rep. Nehls, Troy E. [R-TX-22] (R-TX)
- Rep. Weber, Randy K. Sr. [R-TX-14] (R-TX)
Actions (2)
- Apr 30, 2026 Referred to the House Committee on Energy and Commerce. · house
- Apr 30, 2026 Introduced in House
Similar bills (6)
Bills with similar text or summary — includes reintroductions across Congresses. Ranked by semantic similarity of the bill text (computed locally); a neutral discovery aid, not a claim the bills are duplicates.
Full text
IN THE HOUSE OF REPRESENTATIVES
April 30, 2026
Mr. Rulli (for himself and Mrs. Harshbarger) introduced the following bill; which was referred to the Committee on Energy and Commerce
A BILL
To amend the Public Health Service Act to prohibit treatment of a biologic as a biological product based solely on the presence of a protein that is a clinically inactive component in such biologic, and for other purposes.
Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the “Protecting Equal Access to Thyroid Act of 2026” or the “PEAT Act of 2026”.
SEC. 2. PROHIBITION WITH RESPECT TO TREATMENT OF PROTEINS IN BIOLOGICS.
(a) In General.—Section 351(i)(1) of the Public Health Service Act (42 U.S.C. 262(i)(1)) is amended—
(1) by striking “The term” and inserting the following:
“(A) The term”; and
(2) by adding at the end the following:
“(B) A biologic described in subparagraph (A) may not be treated as a biological product based solely on the presence of a protein that is a clinically inactive component in such biologic.”.
(b) Technical Correction.—Section 351(i)(1) of the Public Health Service Act (42 U.S.C. 262(i)(1)) is amended in subparagraph (A), as designated by subsection (a)(1), by striking “protein ,” and inserting “protein,”. <all>
Comments